Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glioma peptide vaccine - Immatics N.V/BioNTech

Next Previous
X
Search
Drug Profile

Glioma peptide vaccine - Immatics N.V/BioNTech

Alternative Names: Actively personalized vaccines (APVACs); APVAC1; APVAC1-peptide-vaccine; APVAC2; APVAC2-peptide-vaccine

Latest Information Update: 07 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Glioma Actively Personalized Vaccine Consortium
  • Developer BioNTech; Immatics N.V.
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Glioblastoma

Most Recent Events

  • 01 Jul 2020 Immatics N.V and Immatics Biotechnologies GmbH combined to form Immatics N.V.
  • 21 Jun 2019 Glioma peptide vaccine is still in phase I trial for Glioblastoma (GAPVAC website, June 2019)
  • 05 Jul 2018 Immatics completes a phase I trial for Glioblastoma (Adjunctive treatment, Combination therapy, Early-stage disease) in Germany, Switzerland, United Kingdom, Spain, Netherlands, Denmark and USA (Intradermal) (NCT02149225)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top